Dual-engineered imDC-Exo-IKVAV nanovesicles improve locomotor recovery and axonal regeneration in SCI mice
Background
Spinal cord injury (SCI) leads to severe, long-term neurological deficits, primarily due to persistent neuroinflammation, vascular dysfunction, and impaired intrinsic neuronal regeneration. Current therapeutic strategies, including drugs, cell transplantation, and conventional biomaterials, often fall short due to insufficient efficacy, safety concerns, and a lack of coordinated action between immune regulation and neural reconstruction. A critical gap remains in developing treatments that can simultaneously modulate the immune microenvironment and foster neural repair. This study addresses this by leveraging engineered extracellular vesicles to achieve spatiotemporal control over these complex biological processes.
Study Design
Researchers developed an engineered extracellular vesicle platform by decorating immature dendritic cell-derived exosomes (imDC-Exo) with the laminin-mimetic IKVAV peptide. This was achieved using bioorthogonal click chemistry to create imDC-Exo-IKVAV nanovesicles. In vitro experiments assessed the nanovesicles' impact on macrophage inflammatory activation, M2-like polarization, and neural stem cell neuronal differentiation. For in vivo evaluation, SCI mice were administered the imDC-Exo-IKVAV nanovesicles. Primary endpoints included locomotor recovery, macrophage infiltration, inflammatory cytokine production, axonal regeneration, remyelination, and electrophysiological conduction, comparing treated animals to controls.
Results
The engineered imDC-Exo-IKVAV nanovesicles preserved typical exosomal characteristics while integrating the tolerogenic features of imDC-Exo with IKVAV-mediated regenerative cues. In vitro, these nanovesicles significantly reduced macrophage inflammatory activation and promoted an anti-inflammatory phenotype. They also enhanced neural stem cell neuronal differentiation. Following administration in SCI mice, the imDC-Exo-IKVAV nanovesicles successfully accumulated at the injured spinal cord. This accumulation led to notable improvements in locomotor recovery. Mechanistically, the platform alleviated macrophage infiltration and reduced inflammatory cytokine production. It also promoted M2-like polarization of macrophages, which is crucial for tissue repair. Furthermore, the treatment enhanced axonal regeneration and remyelination, critical processes for functional recovery. > The imDC-Exo-IKVAV nanovesicles ultimately restored electrophysiological conduction across the injured spinal cord, demonstrating comprehensive functional and structural repair.
Why It Matters
This research introduces a novel cell-free therapeutic strategy for SCI that effectively coordinates immune microenvironment remodeling with neural repair. By using engineered exosomes decorated with a regenerative peptide, it offers a promising approach to overcome the limitations of current treatments, which often lack integrated immune and regenerative effects. The ability to reduce inflammation, promote M2-like polarization, and enhance both axonal regeneration and remyelination suggests a more holistic recovery pathway. While currently a preclinical animal study, this work lays the groundwork for developing clinically translatable protocols, potentially leading to more effective interventions for patients with SCI. Further research is needed to optimize dosing and delivery for human application.